Cargando…

The Incorporation of Etanercept into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue

Cartilage diseases currently affect a high percentage of the world’s population. Almost all of these diseases, such as osteoarthritis (OA), cause inflammation of this soft tissue. However, this could be controlled with biomaterials that act as an anti-inflammatory delivery system, capable of dosing...

Descripción completa

Detalles Bibliográficos
Autores principales: Campos, Yaima, Fuentes, Gastón, Almirall, Amisel, Que, Ivo, Schomann, Timo, Chung, Chih Kit, Jorquera-Cordero, Carla, Quintanilla, Luis, Rodríguez-Cabello, José C., Chan, Alan, Cruz, Luis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878505/
https://www.ncbi.nlm.nih.gov/pubmed/35214015
http://dx.doi.org/10.3390/pharmaceutics14020282
_version_ 1784658676378763264
author Campos, Yaima
Fuentes, Gastón
Almirall, Amisel
Que, Ivo
Schomann, Timo
Chung, Chih Kit
Jorquera-Cordero, Carla
Quintanilla, Luis
Rodríguez-Cabello, José C.
Chan, Alan
Cruz, Luis J.
author_facet Campos, Yaima
Fuentes, Gastón
Almirall, Amisel
Que, Ivo
Schomann, Timo
Chung, Chih Kit
Jorquera-Cordero, Carla
Quintanilla, Luis
Rodríguez-Cabello, José C.
Chan, Alan
Cruz, Luis J.
author_sort Campos, Yaima
collection PubMed
description Cartilage diseases currently affect a high percentage of the world’s population. Almost all of these diseases, such as osteoarthritis (OA), cause inflammation of this soft tissue. However, this could be controlled with biomaterials that act as an anti-inflammatory delivery system, capable of dosing these drugs over time in a specific area. The objective of this study was to incorporate etanercept (ETA) into porous three-layer scaffolds to decrease the inflammatory process in this soft tissue. ETA is a blocker of pro-inflammatory cytokines, such as tumour necrosis factor alpha (TNF-α) and interleukin 6 (IL-6). For this reason, the scaffold was built based on natural polymers, including chitosan and type I collagen. The scaffold was grafted next to subchondral bone using hydroxyapatite as filler. One of the biomaterials obtained was also crosslinked to compare its mechanical properties with the non-treated one. Both samples’ physicochemical properties were studied with SEM, micro-CT and photoacoustic imaging, and their rheological properties were also compared. The cell viability and proliferation of the human chondrocyte C28/I2 cell line were studied in vitro. An in vitro and in vivo controlled release study was evaluated in both specimens. The ETA anti-inflammatory effect was also studied by in vitro TNF-α and IL-6 production. The crosslinked and non-treated scaffolds had rheological properties suitable for this application. They were non-cytotoxic and favoured the in vitro growth of chondrocytes. The in vitro and in vivo ETA release showed desirable results for a drug delivery system. The TNF-α and IL-6 production assay showed that this drug was effective as an anti-inflammatory agent. In an in vivo OA mice model, safranin-O and fast green staining was carried out. The OA cartilage tissue improved when the scaffold with ETA was grafted in the damaged area. These results demonstrate that this type of biomaterial has high potential for clinical applications in tissue engineering and as a controlled drug delivery system in OA articular cartilage.
format Online
Article
Text
id pubmed-8878505
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88785052022-02-26 The Incorporation of Etanercept into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue Campos, Yaima Fuentes, Gastón Almirall, Amisel Que, Ivo Schomann, Timo Chung, Chih Kit Jorquera-Cordero, Carla Quintanilla, Luis Rodríguez-Cabello, José C. Chan, Alan Cruz, Luis J. Pharmaceutics Article Cartilage diseases currently affect a high percentage of the world’s population. Almost all of these diseases, such as osteoarthritis (OA), cause inflammation of this soft tissue. However, this could be controlled with biomaterials that act as an anti-inflammatory delivery system, capable of dosing these drugs over time in a specific area. The objective of this study was to incorporate etanercept (ETA) into porous three-layer scaffolds to decrease the inflammatory process in this soft tissue. ETA is a blocker of pro-inflammatory cytokines, such as tumour necrosis factor alpha (TNF-α) and interleukin 6 (IL-6). For this reason, the scaffold was built based on natural polymers, including chitosan and type I collagen. The scaffold was grafted next to subchondral bone using hydroxyapatite as filler. One of the biomaterials obtained was also crosslinked to compare its mechanical properties with the non-treated one. Both samples’ physicochemical properties were studied with SEM, micro-CT and photoacoustic imaging, and their rheological properties were also compared. The cell viability and proliferation of the human chondrocyte C28/I2 cell line were studied in vitro. An in vitro and in vivo controlled release study was evaluated in both specimens. The ETA anti-inflammatory effect was also studied by in vitro TNF-α and IL-6 production. The crosslinked and non-treated scaffolds had rheological properties suitable for this application. They were non-cytotoxic and favoured the in vitro growth of chondrocytes. The in vitro and in vivo ETA release showed desirable results for a drug delivery system. The TNF-α and IL-6 production assay showed that this drug was effective as an anti-inflammatory agent. In an in vivo OA mice model, safranin-O and fast green staining was carried out. The OA cartilage tissue improved when the scaffold with ETA was grafted in the damaged area. These results demonstrate that this type of biomaterial has high potential for clinical applications in tissue engineering and as a controlled drug delivery system in OA articular cartilage. MDPI 2022-01-26 /pmc/articles/PMC8878505/ /pubmed/35214015 http://dx.doi.org/10.3390/pharmaceutics14020282 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Campos, Yaima
Fuentes, Gastón
Almirall, Amisel
Que, Ivo
Schomann, Timo
Chung, Chih Kit
Jorquera-Cordero, Carla
Quintanilla, Luis
Rodríguez-Cabello, José C.
Chan, Alan
Cruz, Luis J.
The Incorporation of Etanercept into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue
title The Incorporation of Etanercept into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue
title_full The Incorporation of Etanercept into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue
title_fullStr The Incorporation of Etanercept into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue
title_full_unstemmed The Incorporation of Etanercept into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue
title_short The Incorporation of Etanercept into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue
title_sort incorporation of etanercept into a porous tri-layer scaffold for restoring and repairing cartilage tissue
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878505/
https://www.ncbi.nlm.nih.gov/pubmed/35214015
http://dx.doi.org/10.3390/pharmaceutics14020282
work_keys_str_mv AT camposyaima theincorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT fuentesgaston theincorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT almirallamisel theincorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT queivo theincorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT schomanntimo theincorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT chungchihkit theincorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT jorqueracorderocarla theincorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT quintanillaluis theincorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT rodriguezcabellojosec theincorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT chanalan theincorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT cruzluisj theincorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT camposyaima incorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT fuentesgaston incorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT almirallamisel incorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT queivo incorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT schomanntimo incorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT chungchihkit incorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT jorqueracorderocarla incorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT quintanillaluis incorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT rodriguezcabellojosec incorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT chanalan incorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue
AT cruzluisj incorporationofetanerceptintoaporoustrilayerscaffoldforrestoringandrepairingcartilagetissue